Page last updated: 2024-12-11

phxa 85

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

PhXa 85: RN given for (1R-(1alpha(Z),2beta(R*),3alpha,5alpha))-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6441636
CHEMBL ID1050
CHEBI ID63925
SCHEMBL ID1313159
MeSH IDM0283797

Synonyms (41)

Synonym
latonoprost acid
CHEMBL1050
chebi:63925 ,
latanoprost (free acid form)
latanoprost-free acid
gtpl1960
latanoprost acid, >=98% (hplc)
NCGC00165820-01
41639-83-2
(5z)-7-{(1r,2r,3r,5s)-3,5-dihydroxy-2-[(3r)-3-hydroxy-5-phenylpentyl]cyclopentyl}hept-5-enoic acid
latanprost free acid
latanoprost acid
(z)-7-[(1r,2r,3r,5s)-3,5-dihydroxy-2-[(3r)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoic acid
(z)-7-((1r,2r,3r,5s)-3,5-dihydroxy-2-((r)-3-hydroxy-5-phenylpentyl)-cyclopentyl)hept-5-enoic acid
HNPFPERDNWXAGS-NFVOFSAMSA-N
SCHEMBL1313159
ej85341990 ,
phxa-85
unii-ej85341990
phxa 85
phxa85
13,14-dihydro-17-phenyl-18,19,20-trinor-pgf2alpha
5-heptenoic acid, 7-((1r,2r,3r,5s)-3,5-dihydroxy-2-((3r)-3-hydroxy-5-phenylpentyl)cyclopentyl)-, (5z)-
13,14-dihydro-17-phenyl trinor pgf2.alpha.
13,14-dihydro-17-phenyl-18,19,20-trinor-pgf2.alpha.
latanoprost impurity h [ep impurity]
HMS3648J04
DTXSID6040531
bdbm50485606
CS-0068357
HY-113756A
Q27078867
SR-01000946512-1
sr-01000946512
(z)-7-((1r,2r,3r,5s)-3,5-dihydroxy-2-((r)-3-hydroxy-5-phenylpentyl)cyclopentyl)hept-5-enoic acid
AS-56760
(5z)-7-[(1r,2r,3r,5s)-3,5-dihydroxy-2-[(3r)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoic acid
AKOS037645066
7-[3,5-dihydroxy-2-(3-hydroxy-5-phenylpentyl)cyclopentyl]hept-5-enoic acid
z-7-[(1r,2r,3r,5s)-3,5-bis(oxidanyl)-2-[(3r)-3-oxidanyl-5-phenyl-pentyl]cyclopentyl]hept-5-enoic acid
7wt ,

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Targeting of multiple mechanisms in combination therapies has proven effective both clinically and commercially although potential improvements with regards to efficacy, tolerability and dosing frequency remain."( A multivalent approach towards linked dual-pharmacology prostaglandin F receptor agonist/carbonic anhydrase-II inhibitors for the treatment of glaucoma.
Frieman, B; Hegde, SS; Hill, CM; Jiang, L; Kintz, S; Long, DD; Marquess, DG; Purkey, H; Shaw, JP; Steinfeld, T; Wilson, MS; Wrench, K, 2013
)
0.39
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
antiglaucoma drugAny drug which can be used to prevent or alleviate glaucoma, a disease in which the optic nerve is damaged, resulting in progressive, irreversible loss of vision. It is often, though not always, associated with increased pressure of the fluid in the eye.
antihypertensive agentAny drug used in the treatment of acute or chronic vascular hypertension regardless of pharmacological mechanism.
EC 4.2.1.1 (carbonic anhydrase) inhibitorAn EC 4.2.1.* (hydro-lyases) inhibitor that interferes with the action of carbonic anhydrase (EC 4.2.1.1). Such compounds reduce the secretion of H(+) ions by the proximal kidney tubule.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
prostaglandins Falpha
hydroxy monocarboxylic acidAny monocarboxylic acid which also contains a separate (alcoholic or phenolic) hydroxy substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency0.00350.003245.467312,589.2998AID2517
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier organic anion transporter family member 2A1Homo sapiens (human)Ki0.14900.02300.07000.1490AID679659
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Prostaglandin F2-alpha receptorMus musculus (house mouse)EC50 (µMol)0.01900.00630.01880.0317AID347678; AID726602
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (4)

Processvia Protein(s)Taxonomy
lipid transportSolute carrier organic anion transporter family member 2A1Homo sapiens (human)
sodium-independent organic anion transportSolute carrier organic anion transporter family member 2A1Homo sapiens (human)
transmembrane transportSolute carrier organic anion transporter family member 2A1Homo sapiens (human)
prostaglandin transportSolute carrier organic anion transporter family member 2A1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (3)

Processvia Protein(s)Taxonomy
lipid transporter activitySolute carrier organic anion transporter family member 2A1Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier organic anion transporter family member 2A1Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 2A1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (5)

Processvia Protein(s)Taxonomy
lysosomeSolute carrier organic anion transporter family member 2A1Homo sapiens (human)
plasma membraneSolute carrier organic anion transporter family member 2A1Homo sapiens (human)
basal plasma membraneSolute carrier organic anion transporter family member 2A1Homo sapiens (human)
membraneSolute carrier organic anion transporter family member 2A1Homo sapiens (human)
basolateral plasma membraneSolute carrier organic anion transporter family member 2A1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID726601Intrinsic activity at FP receptor in mouse 3T3 fibroblast cells assessed as maximum compound-evoked response2013Bioorganic & medicinal chemistry letters, Feb-15, Volume: 23, Issue:4
A multivalent approach towards linked dual-pharmacology prostaglandin F receptor agonist/carbonic anhydrase-II inhibitors for the treatment of glaucoma.
AID347700Effect on ocular irritation in New Zealand albino rabbit assessed as incidence of conjunctival swelling 1.8 ug after 1 to 5 hrs2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Discovery of 13-oxa prostaglandin analogs as antiglaucoma agents: synthesis and biological activity.
AID347701Effect on ocular irritation in New Zealand albino rabbit assessed as incidence of ocular discharge 1.8 ug after 1 to 5 hrs2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Discovery of 13-oxa prostaglandin analogs as antiglaucoma agents: synthesis and biological activity.
AID726599Corneal permeability in rabbit corneal tissues mounted on vertical Using chambers2013Bioorganic & medicinal chemistry letters, Feb-15, Volume: 23, Issue:4
A multivalent approach towards linked dual-pharmacology prostaglandin F receptor agonist/carbonic anhydrase-II inhibitors for the treatment of glaucoma.
AID679659TP_TRANSPORTER: inhibition of PGE1 uptake (PGE1: 0.0004 uM) in PGT-expressing HeLa cells2002Experimental eye research, Jan, Volume: 74, Issue:1
Comparison between isopropyl unoprostone and latanoprost by prostaglandin E(2)induction, affinity to prostaglandin transporter, and intraocular metabolism.
AID347678Agonist activity at FP receptor in Swiss mouse 3T3 cells assessed as [3H]-IP accumulation by scintillation counting2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Discovery of 13-oxa prostaglandin analogs as antiglaucoma agents: synthesis and biological activity.
AID726600Permeability across human Caco2 cells2013Bioorganic & medicinal chemistry letters, Feb-15, Volume: 23, Issue:4
A multivalent approach towards linked dual-pharmacology prostaglandin F receptor agonist/carbonic anhydrase-II inhibitors for the treatment of glaucoma.
AID726602Agonist activity at FP receptor in mouse 3T3 fibroblast cells assessed as intracellular calcium mobilization by FLIPR2013Bioorganic & medicinal chemistry letters, Feb-15, Volume: 23, Issue:4
A multivalent approach towards linked dual-pharmacology prostaglandin F receptor agonist/carbonic anhydrase-II inhibitors for the treatment of glaucoma.
AID347677Displacement of [3H]PGF2 alpha from FP receptor in bovine corpus luteum membrane2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Discovery of 13-oxa prostaglandin analogs as antiglaucoma agents: synthesis and biological activity.
AID47783Compound concentration which had a contractile effect on iris sphincter muscle of cats1993Journal of medicinal chemistry, Jan-22, Volume: 36, Issue:2
Phenyl-substituted prostaglandins: potent and selective antiglaucoma agents.
AID347679Agonist activity at FP receptor in Swiss mouse 3T3 cells assessed as [3H]-IP accumulation by scintillation counting relative to control2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Discovery of 13-oxa prostaglandin analogs as antiglaucoma agents: synthesis and biological activity.
AID347699Effect on ocular irritation in New Zealand albino rabbit assessed as incidence of conjunctival hyperemia at 1.8 ug after 1 to 5 hrs2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Discovery of 13-oxa prostaglandin analogs as antiglaucoma agents: synthesis and biological activity.
AID1346394Human FP receptor (Prostanoid receptors)2000Biochimica et biophysica acta, Jan-17, Volume: 1483, Issue:2
The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's3 (30.00)18.2507
2000's6 (60.00)29.6817
2010's1 (10.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]